Fun times at our town #Halloween parade!

Just published in Journal of Clinical Oncology: a review of the emerging evidence in treating oligometastatic disease, with some tips for clinical practice and RCT design.

Led by Western University #radonc grad & @bccancer fellow Wei Liu

#BTV bike path 🍁

⚠️'...only 1.0% to 1.9% of patients with newly diagnosed or recurrent cancer in 2015 participating in an interventional cancer clinical trial'

Wow, need to do better for our Medicare pop - ⬆️trial access, infrastructure, generalizability of trial results

ja.ma/3NgeCJ2

Extremely informative and well attended session on cybersecurity ASTRO #ASTRO22 . It is imperative that we are prepared for future attacks. I encourage everyone to view the virtual talks.

Jean Moran PhD
#medphys
Yat Tsang
Dr. Rebecca M. Howell, PhD
Joseph Deasy, PhD

That’s a wrap, San Antonio

Grateful to participate in a wonderful exchange of data & ideas, and most of all, to see friends and colleagues!

#ASTRO22

BEYOND PROUD of #ASTRO22 &our partners at
ASTRO 🙌

Final Numbers#⃣
40.4Million Impressions (32M in 2021)‼️
2k participants
10,4K Tweets

OncoAlert &
Gil Morgan
9⃣M impressions
2⃣4⃣% of Total impressions

Regardless of Oncology SubSpecialty💊☢️🔪
We're ALL OncoAlert🚨

Friends at #ASTRO22
OncoAlert 🚨functions because of you, we are by Colleagues..For Colleagues🌐

The Network would like to thank Henning Willers, MD (he/him/his) Nat Lester-C🎃ll, MD Shankar Siva for OncoAlert'ing throughout ALL the ASTRO congress&keeping colleagues up to date‼️
Gil Morgan

Final #ASTRO22 Matrix-style data download👇

Hats off to Gil Morgan for these incredibly high-yield summaries!

I didn’t thank the creator of the Cyber session Tony Wang and colleagues C. Jillian Tsai, MD, PhD Nat Lester-C🎃ll, MD James Yu Sidney Kimmel Cancer Center – Jefferson Health ASTRO

#ASTRO22 our series (n=59) of HDR brachytherapy for inoperable endometrial cancer

5-year LFFS 91%, DFS 82%, OS 75%

Only 5 pts died of EC

#gycsm #radonc OncoAlert

The #OncoAlertTopTweet 🚨
DAY3⃣of #ASTRO22

Nat Lester-C🎃ll, MD
MR-Guided On-Table Adaptive Radiation Therapy for Borderline/ Locally Adv Pancreatic Ca
BED10 100 Gy delivered in5⃣fx

✅ 0% Gr+ tox def related to RT, 8.8% possible
✅ 1-year LC 82.9%
✅OS 65.0% from RT
Gil Morgan

The #OncoAlertTopTweet 🚨
DAY3⃣of #ASTRO22

Tweet Nat Lester-C🎃ll, MD

GETUG-AFU 22: immediate salvage for persistently elevated PSA - RT±6 mos
ADT

ADT improved 5⃣year MFS (84 v 79%), though primary endpt (EFS) median not reached

Gil Morgan

The #OncoAlertTopTweet 🚨
DAY3⃣of #ASTRO22

Tweet Nat Lester-C🎃ll, MD

Vedang Murthy w/a great presentation showing us that a steeper decline in absolute/relative nodal SUVmax on PSMA PET w neoadjuvant ADT a/w ⬇️ probability of BCF post RT in node + #prostatecancer

Gil Morgan

Absolutely the best part- so great to see everyone! #ASTRO22

#ASTRO22 Vedang Murthy with a great presentation showing us that a steeper decline in absolute/relative nodal SUVmax on PSMA PET w neoadjuvant ADT a/w ⬇️ probability of BCF post RT in node positive #prostatecancer

#pcsm OncoAlert

#ASTRO22 Nicholas Zaorsky, MD MS presenting IPD meta-analysis of 13 RCTs on optimal duration of ADT

Suggests 19 months LTADT is optimal for OS, and abs risk varies by baseline risk

#pcsm OncoAlert